Showing 2291-2300 of 3139 results for "".
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Crown Aesthetics Adds ProGen PRP Advantage to Portfoliohttps://modernaesthetics.com/news/crown-aesthetics-adds-progen-prp-advantage-to-portfolio/2472870/ProGen PRP Advantage, an easy-to-use, single-spin system that features 15ml and 30ml tubes, yielding 7-15ml of 2x concentration PRP, is now available from Crown Aesthetics, a division of Crown Laboratories, Inc. With the launch of
- Revian: USPTO Grants Patent for Biostimulatory Approachhttps://modernaesthetics.com/news/regina-uspto-grants-patent-for-biostimulatory-approach/2472862/The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the use
- Amorepacific Debuts Face Mask 3D Printing System and Flexible LED Beauty Device at CES 2020https://modernaesthetics.com/news/amorepacific-debuts-face-mask-3d-printing-system-and-flexible-led-beauty-device-at-ces-2020/2472861/Amorepacific is presenting its 3D face mask printing system (IOPE Tailored 3D Mask) and flexible LED beauty device (MakeON Flexible LED Patch) at the Consumer Electronics Show 2020 (CES 2020) in Las Vegas. Created in collaboration with the 3D printing system developer Lincsolu
- AestheticsWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://modernaesthetics.com/news/aestheticswire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2472858/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://modernaesthetics.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt/2472855/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- Alastin Skincare Receives Third Patenthttps://modernaesthetics.com/news/elastin-skincare-receives-third-patent/2472853/Alastin Skincare, Inc. has received a third US Patent from the United States Patent and Trademark Office. The patent covers Alastin’s innovative science and products. US Patent No. 10,493,011 is entitled, "Peptide Compositions and Methods for Ameliorating Skin Laxity and Bod
- Lutronic Introduces the Most Powerful Thulium Laser to Receive FDA Clearancehttps://modernaesthetics.com/news/lutronic-introduces-the-most-powerful-thulium-laser-to-receive-fda-clearance/2472852/Lutronic unveiled the new LaseMD ULTRA™ during live patient demonstrations at the Cosmetic Surgery Forum in Nashville, TN. The LaseMD ULTRA offersthe highest available power that allows for fast treatments, customizable for multiple areas. Additionally, the system providesgen
- Cutera Launches Heroes Among Us Programhttps://modernaesthetics.com/news/cutera-launches-heroes-among-us-program/2472851/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical
- It's A Deal: Baring Private Equity Asia Agrees to Acquire Lumenishttps://modernaesthetics.com/news/its-a-deal-baring-private-equity-asia-agrees-to-acquire-lumenis/2472848/Baring Private Equity Asia’s affiliated private equity funds are acquiring Lumenis. The transaction, which values Lumenis at an enterprise value of more than $1 billion, remains subject to the customary regulatory approval process. It is expected to be completed in early 2020. <